arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Evommune, Inc.

EVMN Health Care Biotechnology: Pharmaceutical Preparations
$12.27
▲ +0.1% Today
as of Sep 4, 16:48 ET
Last 30 days +9.07% Jul 28 → Sep 04
$10.73 $11.88 $13.03 $14.18 $15.33 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$11.87
High
$12.46
Low
$12.02
Volume
$249,080
Avg Vol
$544,265
Mkt Cap
$472M
P/E (TTM)
—
Beta
—
52w High
$33.20
52w Low
$10.47
Div Yield
—
Shares Out
$36M

Recent Press Releases & News last 60 days · 4 items

Aug 26 · 11:29 MT Newswires
Needham Initiates Evommune at Buy With $28 Price Target
Aug 7 · 12:46 MT Newswires
RBC Adjusts PT on Evommune to $29 From $30, Maintains Outperform Speculative Risk Rating
Aug 6 · 20:05 PR Business Wire
Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights
▸ Show all 4 press releases & news Free account →

Overview

52-week range
$10
$33
8% of range
Avg surprise (last 1)
+22.9%
Avg reaction (last 1)
-5.6%
0% positive
Latest IV / EM
310%
EM ±48.5% · $13 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-10.47$-8.01$-5.56$-3.10$-0.64 Actual $-10.47Actual $-9.48Actual $-8.80Actual $-8.07Actual $-0.64Est $-0.83Actual $-0.89 SepMarJunSepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-32M$-22M$-11M$-186,500$10M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.89 — — — — financials
Thu May 7, 2026Mar/2026 $-0.64 $-0.83 +22.9% — -5.6% earnings
Tue Sep 30, 2025Sep 2025 $-8.07 — — — — financials
Mon Jun 30, 2025Jun 2025 $-8.80 — — — — financials
Mon Mar 31, 2025Mar 2025 $-9.48 — — — — financials
Mon Sep 30, 2024Sep 2024 $-10.47 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$0$0—$10M$0$3M——
Cost of revenue————————
Gross profit————————
Operating income$-35M$-24M—$-13M$-23M$-15M—$-17M
Net income$-32M$-22M—$-12M$-14M$-15M—$-16M
EPS (diluted)$-0.89$-0.64—$-8.07$-8.80$-9.48—$-10.47

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$60M$48M$44M$27M$62M$6M$16M$18M
Inventory————————
Total current assets$204M$216M$153M$82M——$74M—
Total assets$302M$322M$225M$85M——$76M—
Long-term debt————————
Total liabilities$24M$18M$19M$11M——$29M—
Total equity$278M$305M$206M$-183M$-171M$-158M$-144M$-123M

Implied volatility — last 90 days

20%158%297%435%573% Jun 08 — IV 191% · EM ±25.3%Jun 17 — IV 574% · EM ±24.0%Jun 19 — IV 245% · EM ±54.1%Jun 22 — IV 267% · EM ±55.7%Jun 23 — IV 270% · EM ±55.3%Jun 24 — IV 257% · EM ±51.6%Jun 25 — IV 279% · EM ±54.7%Jun 26 — IV 267% · EM ±51.0%Jun 29 — IV 100% · EM ±17.7%Jun 30 — IV 123% · EM ±21.2%Jul 01 — IV 157% · EM ±26.2%Jul 02 — IV 149% · EM ±24.1%Jul 03 — IV 154% · EM ±24.1%Jul 06 — IV 196% · EM ±27.1%Jul 07 — IV 163% · EM ±21.6%Jul 08 — IV 39% · EM ±4.9%Jul 09 — IV 28% · EM ±3.3%Jul 10 — IV 20% · EM ±2.2%Jul 13 — IV 114% · EM ±9.5%Jul 14 — IV 144% · EM ±10.4%Jul 15 — IV 88% · EM ±5.2%Jul 16 — IV 368% · EM ±15.4%Jul 20 — IV 59% · EM ±13.9%Jul 21 — IV 192% · EM ±44.6%Jul 22 — IV 160% · EM ±36.6%Jul 23 — IV 153% · EM ±34.5%Jul 24 — IV 132% · EM ±29.1%Jul 27 — IV 167% · EM ±34.9%Jul 28 — IV 239% · EM ±48.9%Jul 29 — IV 226% · EM ±45.2%Jul 30 — IV 196% · EM ±38.3%Jul 31 — IV 232% · EM ±44.4%Aug 03 — IV 212% · EM ±37.5%Aug 04 — IV 137% · EM ±23.6%Aug 05 — IV 130% · EM ±21.7%Aug 06 — IV 127% · EM ±20.6%Aug 07 — IV 155% · EM ±24.1%Aug 10 — IV 267% · EM ±37.0%Aug 11 — IV 29% · EM ±3.8%Aug 13 — IV 60% · EM ±7.1%Aug 14 — IV 349% · EM ±38.6%Aug 19 — IV 79% · EM ±4.7%Aug 24 — IV 144% · EM ±30.0%Aug 25 — IV 170% · EM ±34.8%Aug 26 — IV 189% · EM ±37.9%Aug 27 — IV 177% · EM ±34.7%Aug 31 — IV 223% · EM ±39.5%Sep 01 — IV 109% · EM ±18.8%Sep 02 — IV 224% · EM ±37.5%Sep 03 — IV 258% · EM ±41.7%Sep 04 — IV 310% · EM ±48.5%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in